Overview of 1q abnormalities in multiple myeloma: scientific opinions from Italian experts. in Annals of hematology / Ann Hematol. 2025 Feb 13. doi: 10.1007/s00277-025-06212-5.

2025
ASL Vercelli

Tipo pubblicazione

Review

Autori/Collaboratori (12)Vedi tutti...

D'Agostino M
Division of Hematology, Department of Molecular Biotechnology and Health Sciences, AOU Città della Salute e della Scienza di Torino, University of Torino, Torino, Italy.
Martello M
IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Bologna, Italy.
De Paoli L
Dipartimento di Scienze Mediche e Chirurgiche, Università di Bologna, Bologna, Italy.

et alii...

Abstract

Multiple myeloma (MM) is a haematological malignancy characterised by high genomic heterogeneity. One of the most common cytogenic abnormalities in MM is the gain of genetic material at the long arm (q) of chromosome 1 (+?1q). While many mechanisms of resistance have been associated with +?1q alterations (e.g. CD38 downregulation, impairment of complement-dependent cytotoxicity, or induction of immunosuppression), the precise genetic or pathogenetic factors responsible for these alterations are still being investigated. Although interphase fluorescence in situ hybridisation (iFISH) is the gold standard for the detection of +?1q abnormalities used by the majority of diagnostic laboratories worldwide, there are no universally recognised cut-offs for +?1q positivity or a threshold for clinical meaningfulness. Because iFISH alone is insufficient to elucidate the extent of +?1q and other cytogenetic abnormalities in MM, sequencing-based methods could be adopted. The second revision of the international staging system for MM recently recognised?+?1q as a high-risk feature. There is increasing evidence that +?1q has a prognostic value and influences the duration of remission, suggesting that patients with MM and +?1q may benefit from tailored therapy. This review comprehensively summarises the most recent biological evidence and clinical data on +?1q abnormalities in MM. However, given the heterogeneous data available, it remains difficult to draw firm conclusions. In clinical practice, +1q alterations should be evaluated along with other cytogenetic abnormalities and other biological and clinical characteristics of the disease. Ongoing and future studies will help the full understanding of the role of +?1q in MM.

Accesso banca dati bibliografica

PMID : 39945832

DOI : 10.1007/s00277-025-06212-5

Keywords

+1q; 1q abnormalities; Chromosome 1; Italy; Multiple myeloma;